PAM
AGRX

Premier Asset Management’s Agile Therapeutics AGRX Stock Holding History

Premier Asset Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-112
Closed -$467K – 212
2021
Q1 		$467K Sell
112
-33
-23% -$178K 0.08% 128
2020
Q4 		$829K Buy
145
+50
+53% +$294K 0.17% 83
2020
Q3 		$575K Buy
95
+38
+67% +$218K 0.15% 78
2020
Q2 		$317K Buy
57
+3
+6% +$15.6K 0.11% 92
2020
Q1 		$201K Buy
+54
New +$310K 0.08% 98

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Premier Asset Management's AGRX Position: Q2 2021 in Review

Premier Asset Management sold out of Agile Therapeutics (AGRX) in Q2 2021, closing a stake of 112 shares — an estimated $467K sold.

Premier Asset Management first reported a position in AGRX in Q1 2020 and held it in 5 quarters. The position peaked at $829K in Q4 2020. 64 funds tracked by Wall St. Rank hold AGRX as of Q2 2021.

  • Premier Asset Management reported no remaining Agile Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Premier Asset Management sold 112 Agile Therapeutics shares in Q2 2021, an estimated $467K.
  • Premier Asset Management first reported a position in Agile Therapeutics in Q1 2020 and held it in 5 quarters.
  • Premier Asset Management's Agile Therapeutics position peaked at $829K in Q4 2020.
  • 64 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2021.

Based on Premier Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.